Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 494

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 494
---
ance Under Equity Compensation Plans

The
following table presents information as of December 31, 2024, with respect to shares of our Common Stock that may be issued under our equity incentive plans.

    Plan category 
    Number of securities to be issued upon exercise of outstanding options, warrants, and rights  
    Weighted-average exercise price of outstanding options, warrants, and rights  
    Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) 

    (a)  
    (b)  
    (c) 
  
    Equity compensation plans approved by security holders  

    2024 Equity Incentive Plan 
     519,792  
    $2.00  
     1,480,208 
  
    2014 Equity
Incentive Plan 
     380,132  
    $5.78  
     — 
  
    Equity compensation plans not approved by security holders 
     —  
     —  
     — 
  
    Total 
     899,924  
    $3.59  
     1,480,208 

Item
6. [Reserved.]

Item
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This
section presents management’s perspective on our financial condition and results of operations. The following discussion and analysis
(the “MD&A”) is intended to highlight and supplement data and information presented elsewhere in this Annual Report.
The MD&A is also intended to provide you with information that will assist you in understanding our consolidated financial statements,
the changes in key items in those consolidated financial statements from year to year, and the primary factors that accounted for those
changes. To the extent that this discussion describes prior performance, the descriptions relate only to the periods listed, which may
not be indicative of our future financial outcomes. In addition to historical information, this discussion contains forward-looking statements
that involve risks, uncertainties, and assumptions that could cause the Company’s financial results to differ materially from management’s
expectations. Factors that could cause such differences are discussed in the “Cautionary Note Regarding Forward-Looking Statements”
section of this Annual Report and in the “Risk Factors” in this Annual Report.

 54 

Our
MD&A is organized as follows:

    ●
    Company
    Overview – Discussion of our business plan and strategy to provide context for the remainder of the MD&A.

    ●